NEW MELANOMA DRUG LOOKS PROMISING FOR STAGE III AND IV MELANOMA PATIENTS

51% Of Patients Benefited In Phase II Trial.

Forbes (10/30, Fortonbury) reports that in a study published in Annals of Surgical Oncology, a new cancer drug, PV-10,  51% of stage III and IV melanoma patients benefited during a phase II trial, and achieved total cancer disappearance in 26%. In addition, the response tended to be both rapid and dramatic, with a high rate of response. This drug is extremely promising and is much needed for the treatment of advanced melanoma.  Provectus Biopharmaceuticals, Inc. is the company that engineered PV-10.

Robert S. Bader, M.D., Dermatologist

Recent Posts

Categories

Subscribe!